Ideaya starts Phase 2 of eye melanoma trial

 Initiated Phase 2 clinical trial evaluating Darovasertib as neoadjuvant treatment of uveal melanoma prior to primary interventional treatment of enucleation or radiation therapy

-  Clinical protocol includes neoadjuvant treatment with Darovasertib to maximum benefit up to 6 months, primary treatment, then up to 6 months of follow-up adjuvant therapy

-  Neoadjuvant endpoints include eye preservation, reducing radiation and vision preservation; adjuvant endpoints include relapse free survival and useful vision

-  UM represents an unmet medical need and potential clinical expansion opportunity with annual incidence of approximately 8,700 patients in the US and EU

-  Targeting clinical data update for Darovasertib / Crizotinib Combination in MUM in 2023, including overall survival (OS) data

https://finance.yahoo.com/news/ideaya-announces-darovasertib-phase-2-110000420.html